Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100751 | 0.94 | POLB (0.40) | ALKLRRK2KITPOLBPIK3CA | |
| SCHEMBL10100462 | 0.93 | SMN1; SMN2 (0.37) | KITPIK3CAAXLPIK3R1KDR | |
| SCHEMBL10100430 | 0.92 | SMN1; SMN2 (0.39) | KITPIK3CAAXLPIK3R1KDR | |
| SCHEMBL10100594 | 0.91 | MET (0.42) | ALKLRRK2KITPIK3CAMET | |
| SCHEMBL10100561 | 0.91 | ABL1 (0.39) | ALKLRRK2KITPIK3CAMET | |
| SCHEMBL10100384 | 0.91 | MET (0.41) | ALKLRRK2KITPIK3CAMET | |
| SCHEMBL10100592 | 0.91 | NTRK1 (0.41) | ALKLRRK2KITPIK3CAMET | |
| SCHEMBL10100596 | 0.90 | MET (0.43) | ALKLRRK2KITPIK3CAMET | |
| SCHEMBL10100559 | 0.89 | KIT (0.37) | ALKLRRK2KITPOLBPIK3CA | |
| SCHEMBL10100569 | 0.88 | KDR (0.41) | ALKLRRK2KITPIK3CAMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2010048131-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | ALK 107/4885LRRK2 856/4885KIT 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.